Skip to main content

Covid-19 (Coronavirus) Epidemic in the UK - Update 16 March 2020

How will the Covid-19 (coronavirus) epidemic in the UK develop? In February 2020, there were sporadic cases across the UK and in March 2020, we saw a more sustained increase in cases. Based on current trends, the total cumulative number of cases of COVID-19 in UK could reach  21,264 (95% CIs: 14881 to 30459 ) in another 10 days, using data published on 15 March 2020.

We have assumed that each day's cases are a fixed proportion of the total cases up to the day before. It is also assumed the rate will not change in the next 7 days; e.g., it is not going to be influenced by new interventions, increased self-isolation and other factors.

To estimate confidence intervals, we used the prediction confidence intervals from the linear regression model (using logarithm of "cumulative number of cases" as response) to perform Monte Carlo simulations to generate samples from the corresponding normal distribution. Subsequently, we applied the reverse transformation (exponential) to the simulated samples and calculated the 95% confidence Intervals.

If the number of cases is below predictions, this would imply that control measures and behavioural change are having some impact in keeping numbers down. It could also though reflect changes in the policy for testing people who are suspected cases. We will update chart this regulary if we can get reliable data about the number of Covid-19 cases in the UK and the data is not skewed by the government decision to cut back on community testing.

Azeem Majeed and Mansour Taghavi Azar Sharabiani

Doubling time (days): 2.6
Prediction for next 10 days:
16/03/2020 1913  ( 1426 ,  2568 )
17/03/2020 2500  ( 1852 ,  3381 )
18/03/2020 3267  ( 2403 ,  4431 )
19/03/2020 4270  ( 3122 ,  5814 )
20/03/2020 5580  ( 4053 ,  7683 )
21/03/2020 7291  ( 5259 ,  10101 )
22/03/2020 9528  ( 6811 ,  13283 )
23/03/2020 12452  ( 8844 ,  17529 )
24/03/2020 16272  ( 11466 ,  23140 )
25/03/2020 21264  ( 14881 ,  30459 )



Comments

Popular posts from this blog

The Hidden Cost of Cheaper NHS Contracts: Losing Community Trust

NHS budgets are under considerable pressure. It is therefore unsurprising that many NHS Integrated Care Boards (ICBs) In England will aim to prioritise price in contract awards, But this approach is a significant threat to community-centred healthcare. While competitive tendering is a legally required, an excessive focus on costs in awarding NHS contracts risks overshadowing key factors such as established community trust, local expertise, and the long-term impact on continuity of care. This shift towards cheaper, often external, commercial providers threatens to cut the links between communities and their local health services. The argument that competitive tendering is solely about legal compliance, and not cost, is undermined by the very nature of such tendering, which by design encourages the lowest bid. This approach risks eroding the social fabric of local healthcare provision, where established relationships and understanding of specific community needs are essential. Establishe...

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...